Valneva (VALN) AI Stock Analysis

• Market Cap: $887.72M
• Dividend Yield: N/A
• Average Volume (3M): 20.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 14.86%
• EPS Growth: -1440.45%
• Country: US
• Employees: 713
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 86,106,740
• 10 Day Avg. Volume: 18,549
• 30 Day Avg. Volume: 20,669
• PEG Ratio: 0.27
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 1.75
• P/FCF Ratio: -3.54
• Enterprise Value/Market Cap: 1.25
• Enterprise Value/Revenue: 5.65
• Enterprise Value/Gross Profit: 11.52
• Enterprise Value/Ebitda: -27.07
• 1Y Price Target: $10.28
• Price Target Upside: 2.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $10.50 ▲(4.58% Upside)

Valneva's overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company's high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.

Positive Factors

Revenue Growth

The consistent revenue growth indicates Valneva's expanding market presence and successful product adoption, supporting long-term business stability.

Debt Refinancing

Refinancing improves financial flexibility, allowing Valneva to focus on strategic initiatives and reduce financial risk, supporting sustainable growth.

Lyme Disease Vaccine Development

Advancing Lyme disease vaccine development positions Valneva to capture market share in an unmet medical need, driving future revenue growth.

Negative Factors

High Leverage

High leverage poses financial risks and limits flexibility, potentially impacting Valneva's ability to invest in growth and manage economic downturns.

Negative Profitability

Sustained negative profitability indicates challenges in cost management and revenue generation, threatening long-term financial health and growth potential.

Cash Flow Challenges

Negative cash flow highlights operational inefficiencies and could hinder Valneva's ability to fund R&D and strategic initiatives, affecting future growth.

Valneva Business Overview & Revenue Model

Company Description

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

How the Company Makes Money

Valneva generates revenue primarily through the development and commercialization of its vaccine products. The company's revenue streams include sales from licensed vaccines, government contracts, and partnerships with other pharmaceutical companies for research and development. Valneva has entered into significant collaborations, such as its partnership with the British government for the development of its COVID-19 vaccine, which provides funding and potential revenue from future vaccine sales. Additionally, Valneva may receive milestone payments and royalties from its collaborations, further contributing to its earnings. The company also seeks to expand its market presence through strategic partnerships that enhance its product pipeline and distribution capabilities.

Valneva Financial Statement Overview

Summary

Valneva's financial statements reflect challenges with profitability and cash flow. Despite a healthy gross profit margin, the company faces high leverage and negative profitability metrics. Revenue growth is modest, but operational efficiency and debt management need improvement.

Income Statement

Valneva's income statement shows a mixed performance. The TTM gross profit margin is relatively healthy at 46.56%, indicating efficient cost management. However, the net profit margin is negative at -43.21%, reflecting ongoing losses. Revenue growth is modest at 5.52% TTM, but the company has struggled with profitability, as evidenced by negative EBIT and EBITDA margins. The company needs to focus on improving operational efficiency and profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.20 TTM, indicating significant leverage, which could pose financial risks. The return on equity is negative, suggesting that the company is not generating sufficient returns on shareholders' equity. The equity ratio is moderate, but the company needs to manage its debt levels to improve financial stability.

Cash Flow

Cash flow analysis shows challenges, with negative operating cash flow and free cash flow TTM. The free cash flow growth rate is negative, indicating declining cash generation. The operating cash flow to net income ratio is also negative, highlighting cash flow issues. The company must enhance cash flow management to support its operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.33M	169.58M	153.71M	361.30M	348.08M	110.32M
Gross Profit	96.25M	71.04M	52.84M	36.86M	160.16M	56.02M
EBITDA	-40.98M	32.08M	-57.72M	-104.72M	-38.73M	-44.76M
Net Income	-67.04M	-12.25M	-101.43M	-143.28M	-73.42M	-64.39M
Balance Sheet
Total Assets	472.63M	500.03M	460.06M	621.34M	817.35M	449.16M
Cash, Cash Equivalents and Short-Term Investments	161.31M	168.27M	126.08M	289.43M	346.64M	204.39M
Total Debt	196.92M	216.31M	208.82M	152.38M	114.66M	105.45M
Total Liabilities	286.19M	318.78M	331.81M	401.55M	646.77M	371.74M
Stockholders Equity	186.43M	181.25M	128.25M	219.80M	170.58M	77.42M
Cash Flow
Free Cash Flow	-34.39M	-83.66M	-217.06M	-274.67M	-16.27M	118.27M
Operating Cash Flow	-11.90M	-67.22M	-202.74M	-245.34M	76.90M	137.74M
Investing Cash Flow	-12.33M	76.92M	-20.59M	-29.05M	-93.12M	-19.34M
Financing Cash Flow	56.57M	30.68M	63.08M	215.12M	154.50M	21.74M

Valneva Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VALN, the sentiment is Positive. The current price of 10.04 is above the 20-day moving average (MA) of 8.99, above the 50-day MA of 8.93, and above the 200-day MA of 8.14, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 69.17 is Neutral, neither overbought nor oversold. The STOCH value of 91.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VALN.

Valneva Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	53 Neutral	$1.38B	-14.22	-64.93%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SANA	51 Neutral	$1.26B	-4.88	-96.11%	―	―	31.16%
URGN	50 Neutral	$877.20M	-5.41	―	―	8.00%	-10.15%
ABUS	49 Neutral	$919.31M	-21.55	-45.88%	―	116.64%	47.93%
VALN	48 Neutral	$887.72M	-7.56	-54.42%	―	14.86%	-1440.45%
IVA	47 Neutral	$1.13B	-1.47	―	―	-12.52%	-82.84%

Valneva Corporate Events

Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data

On January 9, 2026, Valneva announced that its management team, including CEO Thomas Lingelbach and CFO Peter Bühler, will hold one-on-one meetings with existing shareholders and other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–14, 2026, in San Francisco. The executives plan to discuss upcoming catalysts from Valneva’s clinical pipeline—most notably a pivotal data readout for its Lyme disease vaccine expected in the first half of 2026—alongside the performance of its commercial vaccine portfolio, signaling an effort to strengthen investor engagement and highlight the company’s late-stage assets and growth prospects.

The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends

On December 31, 2025, Valneva SE and Serum Institute of India announced they had mutually agreed to discontinue their license agreement covering Valneva’s single-shot chikungunya vaccine. By regaining full rights to the product, Valneva aims to take direct control of supply and commercialization in endemic high-risk countries, a shift intended to accelerate access in regions most affected by chikungunya and to align with its July 2024 funding agreement with CEPI, co-funded by the European Union, to support vaccine access in low- and middle-income countries. The move underscores Valneva’s strategy to tighten control over key assets in its portfolio and could strengthen its positioning in the growing market for vaccines against climate-sensitive vector-borne diseases, as chikungunya is spreading across more than 110 countries and is recognized by the WHO as a major public health problem.

The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children

Valneva SE announced positive final results from its Phase 2 clinical trial for the chikungunya vaccine IXCHIQ® in children aged one to eleven years. The trial demonstrated that the vaccine was well tolerated and maintained high antibody levels twelve months post-vaccination, supporting the selection of a full dose for future Phase 3 trials. The strong immune response and favorable safety profile observed in children align with previous findings in adolescents and adults. The company plans to gather additional real-world data in adolescents before proceeding with Phase 3 trials in children, highlighting the importance of a long-term protective vaccine for chikungunya, especially in regions with limited vaccine access.

The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Valneva Announces Strategic Consolidation of French Operations

On November 26, 2025, Valneva SE announced a strategic initiative to consolidate its operations in France, focusing its activities at the Lyon site and closing its Nantes location to streamline operations and improve efficiency. This move is part of Valneva’s efforts to enhance operational effectiveness and position itself for long-term success. The consolidation will also centralize all R&D activities in Vienna. The company is committed to supporting its employees during this transition, ensuring a smooth process for all affected team members.

The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments

On November 26, 2025, Valneva SE announced its financial results for the first nine months of 2025, reporting total revenues of €127.0 million, an 8.9% increase from the previous year. Despite a net loss of €65.2 million, the company achieved significant financial flexibility through successful debt refinancing and reduced operating cash burn. Valneva’s Lyme disease vaccine candidate, VLA15, is progressing well in its Phase 3 study, with results expected in 2026. The company also highlighted the growth in sales of its Japanese encephalitis vaccine and the launch of its chikungunya vaccine, IXCHIQ®, despite regulatory challenges in the U.S.

The most recent analyst rating on (VALN) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Valneva Reports Increased Revenues and Strategic Advances in Vaccine Development

On November 20, 2025, Valneva SE reported its financial results for the first nine months of 2025, highlighting an 8.9% increase in total revenues to €127.0 million compared to the same period in 2024. The company achieved significant financial flexibility through successful debt refinancing and reduced operating cash burn. Despite a net loss of €65.2 million, Valneva’s commercial portfolio showed growth, particularly in its Japanese encephalitis vaccine sales. The company is advancing its Lyme disease vaccine candidate with Pfizer, expecting Phase 3 results in 2026, and is also progressing with its Shigella vaccine candidate, which received Fast Track designation from the FDA.

The most recent analyst rating on (VALN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Valneva Reports Positive Phase 1 Results for Zika Vaccine Candidate

Valneva SE announced positive results from its Phase 1 clinical trial of VLA1601, a second-generation adjuvanted inactivated vaccine candidate against the Zika virus. Conducted in the United States with approximately 150 participants, the trial demonstrated that VLA1601 was generally safe and well tolerated, with no safety concerns identified. The strongest immune response was observed in the double-adjuvant treatment arms, showing significantly higher neutralizing antibody titers compared to the single-adjuvant arm. These results indicate an improved immune response over the first-generation vaccine candidate, but further development will depend on securing major funding opportunities.

The most recent analyst rating on (VALN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.